Cardio-Oncology Forum-3
|
08:00-10:00 403 |
|---|
| 主持 Moderators | 董颖 Ying DONG, 盛夏 Xia SHENG, 高丹忱 Danchen GAO, 陈治奎 Zhikui CHEN | ||
|
08:00-08:20 |
肿瘤相关静脉血栓诊断、预防及治疗 Diagnosis, Prevention and Treatment of Cancer-Associated Venous Thromboembolism |
邵群 Qun SHAO | |
|
08:20-08:40 |
生物标志物心脏损伤 Biomarkers for Cardiac Injury |
张玉玲 Yuling ZHANG | |
|
08:40-09:00 |
肿瘤患者合并冠脉临界病变的处理原则 Management Principles of Coronary Borderline Lesions in Cancer Patients |
屠晓鸣 Xiaoming TU | |
|
09:00-09:20 |
肿瘤心脏病学研究热点 Research Hotspots in Cardio-Oncology |
白明 Ming BAI | |
|
09:20-09:40 |
ICI相关心血管毒性：真实世界特征与临床对策 ICI-Related Cardiovascular Toxicity: Real-World Characteristics and Clinical Countermeasures |
徐慧敏 Huimin XU | |
|
09:40-10:00 |
讨论 Discussion |
||
Cardio-Oncology Forum-4
|
10:00-12:00 403 |
|---|
| 主持 Moderators | 何红 Hong HE, 朱敏 Min ZHU, 池菊芳 Jufang CHI, 沈虹 Hong SHEN, 李闪 Shan LI | ||
|
10:00-10:20 |
2025肿瘤心脏病学与心衰：美国心衰协会科学声明解读 2025 Cardio-Oncology and Heart Failure: Interpretation of the Scientific Statement by the Heart Failure Society of America |
刘莹 Ying LIU | |
|
10:20-10:40 |
肿瘤合并泛血管病变 Cancer Complicated with Pan-Vascular Diseases |
程蕾蕾 Leilei CHENG | |
|
10:40-11:00 |
乳腺肿瘤治疗相关心血管损伤 Cardiovascular Injury Related to Breast Cancer Treatment |
陈占红 Zhanhong CHEN | |
|
11:00-11:20 |
肿瘤相关高血压整合管理中国专家共识解读 Interpretation of the Chinese Expert Consensus on Integrated Management of Cancer-Related Hypertension |
高丹忱 Danchen GAO | |
|
11:20-11:40 |
肿瘤创新靶点在未来治疗展望 Future Treatment Outlook of Novel Cancer Targets |
赵菁 Jing ZHAO | |
|
11:40-12:00 |
肿瘤药物不良反应管理 Management of Adverse Reactions to Cancer Drugs |
经霄 Xiao JING | |
Metabolic & CVD Forum-4
|
13:30-15:30 403 |
|---|
| 主持 Moderators | 谢小洁 Xiaojie XIE, 张岩 Yan ZHANG, 王胜煌 Shenghuang WANG | ||
| 讨论嘉宾 Discussants | John R. Nelson, 李建平 Jianping LI, 阮雄中 Xiongzhong RUAN, 李建军 Jianjun LI | ||
|
13:30-13:35 |
致辞 Opening Remarks |
王建安 Jianan WANG | |
|
13:35-14:00 |
中外论道：聚焦国内外最新血脂前沿 1、ASCVD剩留风险的现状和研究进展 2、剩留风险的评估指标 3、剩留风险的靶点和新药研究 Sino-Foreign Dialogue: Focus on the Latest Domestic and International Lipid Frontiers 1. Current Status and Research Progress of ASCVD Residual Risk 2. Evaluation Indicators of Residual Risk 3. Targets and New Drug Research for Residual Risk |
||
|
14:00-14:20 |
降低高甘油三酯血症患者的残余心血管风险：二十碳五烯酸的独特作用 Reducing Residual Cardiovascular Risk in Patients with Hypertriglyceridemia: the Unique Role of Eicosapentaenoic acid |
John R. Nelson | |
|
14:20-14:40 |
降脂新药研究进展 Research Progress of New Lipid-Lowering Drugs |
李建平 Jianping LI | |
|
14:40-15:00 |
代谢共病的脂代谢特点与临床对策 Lipid Metabolism Characteristics and Clinical Countermeasures of Metabolic Comorbidities |
阮雄中 Xiongzhong RUAN | |
|
15:00-15:20 |
VAP技术检测血脂与脂蛋白亚组分及其临床应用中国专家共识（2025版）解读 Interpretation of the Chinese Expert Consensus on the Detection of Blood Lipids and Lipoprotein Subfractions by VAP Technology and Their Clinical Application (2025 Edition) |
鄢盛恺 Shengkai YAN | |
|
15:20-15:30 |
总结 Summary |
||
Metabolic & CVD Forum-5
|
15:30-17:30 403 |
|---|
| 主持 Moderators | 陈晓敏 Xiaomin CHEN, 刘炳辰 Bingchen LIU, 曾春来 Chunlai ZENG | ||
| 讨论嘉宾 Discussants | 单培仁 Peiren SHAN, 廉姜芳 Jiangfang LIAN, 米亚非 Yafei MI, 陈巧莉 Qiaoli CHEN | ||
|
15:30-15:40 |
开场致辞 Opening Remarks |
||
|
15:40-16:00 |
从CKM到SMD：欧洲动脉粥样硬化学会专家共识体现ASCVD管理哪些新思路 From CKM to SMD: What New Ideas for ASCVD Management are Reflected in the Expert Consensus of the European Atherosclerosis Society |
邱春光 Chunguang QIU | |
|
16:00-16:20 |
从FLOW研究结果谈心肾代谢疾病的管理 Management of Cardiorenal Metabolic Diseases Based on the Results of the FLOW Study |
梁春 Chun LIANG | |
|
16:20-16:40 |
口服GLP-1RAT2DM患者心血管代谢获益新选择 New Option for Cardiovascular and Metabolic Benefits in T2DM Patients Treated with Oral GLP-1RA |
杨建敏 Jianmin YANG | |
|
16:40-17:00 |
糖尿病合并心肌梗死+CTO Management of CTO in Patients with MI and Diabetes |
朱建兵 Jianbing ZHU | |
|
17:00-17:20 |
讨论 Discussion |
||
|
17:20-17:30 |
总结 Summary |
||